Clinical trials have demonstrated that Zalifrelimab (anti-CTLA-4) and Balstilimab (anti-PD-1) possess acceptable safety profiles and induce sustained responses, highlighting their potential as effective therapies for advanced cervical cancer (63). The gene discussed is CTLA4; the disease is cervical cancer.